DE60302454T2 - Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen - Google Patents

Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen Download PDF

Info

Publication number
DE60302454T2
DE60302454T2 DE60302454T DE60302454T DE60302454T2 DE 60302454 T2 DE60302454 T2 DE 60302454T2 DE 60302454 T DE60302454 T DE 60302454T DE 60302454 T DE60302454 T DE 60302454T DE 60302454 T2 DE60302454 T2 DE 60302454T2
Authority
DE
Germany
Prior art keywords
group
alkyl
groups
ono
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60302454T
Other languages
German (de)
English (en)
Other versions
DE60302454D1 (de
Inventor
Abdullah Ibrahim Haj-Yehia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of DE60302454D1 publication Critical patent/DE60302454D1/de
Application granted granted Critical
Publication of DE60302454T2 publication Critical patent/DE60302454T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DE60302454T 2002-04-19 2003-04-15 Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen Expired - Fee Related DE60302454T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37417302P 2002-04-19 2002-04-19
US374173P 2002-04-19
PCT/IL2003/000312 WO2003088961A1 (en) 2002-04-19 2003-04-15 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders

Publications (2)

Publication Number Publication Date
DE60302454D1 DE60302454D1 (de) 2005-12-29
DE60302454T2 true DE60302454T2 (de) 2006-08-17

Family

ID=29251152

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60302454T Expired - Fee Related DE60302454T2 (de) 2002-04-19 2003-04-15 Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen

Country Status (7)

Country Link
US (2) US7378438B2 (enExample)
EP (1) EP1503754B1 (enExample)
JP (1) JP2005533013A (enExample)
AT (1) ATE310514T1 (enExample)
AU (1) AU2003226603A1 (enExample)
DE (1) DE60302454T2 (enExample)
WO (1) WO2003088961A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003226603A1 (en) 2002-04-19 2003-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
AU2003283789A1 (en) * 2002-11-22 2004-06-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
JP2006206521A (ja) * 2005-01-28 2006-08-10 Univ Of Tokyo 一酸化窒素供与体としてのｎ−ニトロソアミン化合物
TWI657070B (zh) * 2005-06-24 2019-04-21 美商哈尼威爾國際公司 含有經氟取代之烯烴之組合物及其用途
GB0708392D0 (en) * 2007-05-01 2007-06-06 Clearway Medical Ltd Breathing device
JP2013518097A (ja) 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
WO2012037665A1 (en) * 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
WO2012093383A1 (en) * 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
CN103018452B (zh) * 2011-09-20 2016-01-13 北京勤邦生物技术有限公司 一种检测沙丁胺醇药物的胶体金试纸卡及检测方法
WO2014169976A1 (en) * 2013-04-18 2014-10-23 Nicox Science Ireland Quinone based nitric oxide donating compounds
US10064583B2 (en) 2013-08-07 2018-09-04 Covidien Lp Detection of expiratory airflow limitation in ventilated patient
SG11201601291QA (en) * 2013-08-23 2016-03-30 Parion Sciences Inc Dithiol mucolytic agents
SG11201705790SA (en) 2015-01-30 2017-08-30 Parion Sciences Inc Novel monothiol mucolytic agents
US10441568B2 (en) * 2015-03-26 2019-10-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nitroxide radicals for the treatment of diseases of the respiratory tract
JP2018520986A (ja) 2015-04-30 2018-08-02 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解剤の新規なプロドラッグ
WO2018067838A1 (en) * 2016-10-07 2018-04-12 The University Of North Carolina At Chapel Hill S-nitrosothiol-mediated hyperbranched polyesters
EP3565848A4 (en) 2017-01-03 2020-09-02 The University of North Carolina at Chapel Hill NITRIC OXIDE RELEASING ALGINATES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES
EP3600338A4 (en) 2017-03-28 2020-10-28 The University of North Carolina at Chapel Hill NITRIC OXIDE RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES
CN111491982B (zh) 2017-11-15 2023-04-18 北卡罗来纳大学查佩尔希尔分校 作为抗菌支架的一氧化氮释放型超支化化合物及其相关方法
JP7565588B2 (ja) 2018-03-06 2024-10-11 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 生分解性の抗菌性足場としての一酸化窒素放出性シクロデキストリンおよびそれに関する方法
WO2020139857A1 (en) 2018-12-28 2020-07-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
CN112745251B (zh) * 2019-10-31 2023-10-27 华创合成制药股份有限公司 一种治疗祛痰化合物及其制备方法和用途
WO2022251679A1 (en) * 2021-05-27 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide radicals for use as antiviral treatment for coronavirus infection

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US6297762B1 (en) 1979-06-27 2001-10-02 Raytheon Company Electronic countermeasures system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
DE69027319T2 (de) 1989-04-28 1996-11-21 Riker Laboratories Inc., Northridge, Calif. Inhalationsvorrichtung für trockenpulver
JP3085705B2 (ja) 1990-01-05 2000-09-11 セプラカー・インコーポレーテツド 喘息の治療のための光学的純粋ｒ（−）アルブテロール
US5364833A (en) 1990-05-09 1994-11-15 Basf Aktiengesellschaft Cyclohexenone oxime ethers, their preparation and their use as herbicides
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5492112A (en) 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US5821259A (en) 1991-11-12 1998-10-13 Theoharides; Theoharis C. H3 -receptor agonists as therapeutic agents
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US5277195A (en) 1992-02-03 1994-01-11 Dura Pharmaceuticals, Inc. Portable spirometer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
WO1994008552A2 (en) 1992-10-19 1994-04-28 Dura Pharmaceuticals, Inc. Dry powder inhaler
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
JPH08509465A (ja) 1993-01-29 1996-10-08 マイリス メディカル コーポレーション ホルモンの肺内送達
US6131567A (en) 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
CA2183577C (en) 1994-03-07 2007-10-30 John S. Patton Methods and compositions for pulmonary delivery of insulin
RU2145595C1 (ru) 1994-05-10 2000-02-20 Никокс С.А. Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности
US5986076A (en) * 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5686878A (en) * 1995-04-03 1997-11-11 Gueli; Carmen Temperature sensitive fusible link assembly having cooperating projections and slots
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
AU6031096A (en) 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
WO1999040787A1 (en) 1998-02-13 1999-08-19 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
IN188837B (enExample) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
US6277884B1 (en) 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
CA2352144A1 (en) 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds
CN1526448A (zh) 1998-12-14 2004-09-08 ���ռ�ҩ��ɷ����޹�˾ 用于治疗肛门直肠病的药物和方法
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
AU3139500A (en) 1999-03-11 2000-09-28 University Of Manitoba Modulation of skeletal muscle precursor cell activation
GB2349385A (en) 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
SE9903985D0 (sv) 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
US6492405B2 (en) 1999-12-30 2002-12-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nitric oxide donors and pharmaceutical compositions containing them
AU2001226029A1 (en) 2000-01-10 2001-07-24 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
AU2003226603A1 (en) 2002-04-19 2003-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders

Also Published As

Publication number Publication date
JP2005533013A (ja) 2005-11-04
US20050228184A1 (en) 2005-10-13
US7378438B2 (en) 2008-05-27
EP1503754A1 (en) 2005-02-09
EP1503754B1 (en) 2005-11-23
DE60302454D1 (de) 2005-12-29
AU2003226603A1 (en) 2003-11-03
WO2003088961A1 (en) 2003-10-30
ATE310514T1 (de) 2005-12-15
US20080149097A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
DE60302454T2 (de) Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
DE69633442T2 (de) Neue substituierte piperazinderivate mit tachykininrezeptor-antagonistischer wirkung
US6436998B1 (en) Use of gamma-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism
ES2393230T3 (es) Uso farmacéutico de amidas sustituidas
EP1694318B1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum
DE69833748T2 (de) Benzocycloheptha-thiophen verbindungen
DE60107435T2 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
EP0929516B1 (de) Benzamidinderivate und ihre verwendung als arzneimittel mit ltb4-antagonistischer wirkung
DD201139A5 (de) Verfahren zur herstellung von (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamin und seinen pharmazeutisch unbedenklichen salzen
SK282566B6 (sk) Deriváty benzimidazolu, farmaceutický prostriedok a použitie
WO2010003127A2 (en) Antagonists of prostaglandin d2 receptors
DD202001A5 (de) Verfahren zur herstellung von aminoaethanolen
WO2004012648A2 (de) Substituierte diarylheterocyclen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PL121297B1 (en) Process for preparing novel derivatives of phenethanolamine
DE10201550A1 (de) Phenoxy-Piperidine
PL154186B1 (en) Method for manufacturing arylic derivatives of the hydroxamic acid
JP3008195B2 (ja) 抗炎症組成物
EP0374756A2 (de) Stickstoffhaltige Ringverbindungen
EP0089028B1 (de) Neue Theophyllin-Derivate und Verfahren zu ihrer Herstellung
US2770649A (en) o-methoxyphenoxy-2-hydroxy-propyl carbamates
DE2719576A1 (de) Arzneimittel
DE2653147C2 (enExample)
EP3235815A1 (de) Wirkstoffe gegen parasitäre helminthen
DD260494A5 (de) Verfahren zur herstellung von alpha-hydroxythiotherm
DD295846A5 (de) Verfahren zur herstellung weiterer neuer alkanophenone

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee